Key Takeaways
- Three years of semaglutide or tirzepatide was associated with a nearly 5 percentage point lower eight-year risk of knee replacement in a matched cohort of adults with knee osteoarthritis.
- A head-to-head meta-analysis of 41,381 participants found tirzepatide delivered 4.28 points more weight loss than semaglutide but carried an 83% higher risk of serious adverse events.
- One-year persistence on weight-loss GLP-1s among commercially insured adults nearly doubled, from 33.2% in 2021 to 60.9% in the first half of 2024.
- Employer coverage of GLP-1s for obesity dropped from 72% in 2025 to 60% in 2026, and 14% of employers have dropped or plan to drop it by 2027.
For most of the GLP-1 era, the case against broad coverage rested on two arguments: the benefits beyond weight loss were unproven, and patients quit too quickly for anyone to capture them. Both arguments are weakening. Real-world data now ties longer GLP-1 use to fewer joint replacements, and patients are staying on therapy far longer than they did three years ago. Yet the payers who would collect those downstream savings are heading the other way. Employer coverage for obesity treatment has fallen twelve points in a single year, and the drugmakers behind these molecules are left with a strengthening clinical story and a shrinking commercial audience.
The Outcomes Case Is Moving Beyond the Scale
The most striking new signal comes from orthopedics. A study published June 2 in Regional Anesthesia & Pain Medicine, drawing on anonymized records in the TriNetX Global Research Network, followed propensity-matched adults with knee osteoarthritis, including 42,062 patients treated with any GLP-1 for one year. According to the BMJ Group's summary of the findings, one year of any GLP-1 was linked to a 1.4 percentage point lower cumulative risk of knee replacement at three years, widening to nearly 3 points by year eight. Among 13,351 patients who took semaglutide or tirzepatide for three years, the eight-year reduction approached 5 percentage points.
The researchers translated the effect into national terms: a 1.44 point absolute reduction would mean roughly 14,400 fewer total knee replacements a year in the United States. The design is observational, so it cannot prove the drugs caused the difference, but the duration-dependent pattern is the kind of real-world evidence that payers and health technology assessors increasingly weigh. For sponsors, it is a reminder that the value dossier for incretin therapies will be written as much in claims data and surgical registries as in pivotal trials.
The picture between molecules is more nuanced. A systematic review and meta-analysis of ten head-to-head studies covering 41,381 participants, published August 30 in Clinical Obesity, found tirzepatide produced 4.28 percentage points more weight reduction than semaglutide, 4.43 kg more absolute weight loss, and a 0.29 point greater drop in HbA1c. Serious adverse events, however, were more frequent with tirzepatide (risk ratio 1.83), even though gastrointestinal events and treatment discontinuation did not differ significantly. The authors framed it as a clinical trade-off requiring individualized decisions, which is exactly the kind of nuance that blanket coverage exclusions erase.
Patients Are Staying On, and That Changes the Math
The second pillar of the skeptics' case was persistence. If most patients stop within months, the downstream savings never arrive. That assumption is now dated. A Prime Therapeutics analysis published in the Journal of Managed Care & Specialty Pharmacy tracked 33,607 commercially insured adults without diabetes who started high-potency weight-loss GLP-1s across 19 health plans. One-year persistence climbed from 33.2% in 2021 to 60.9% in the first half of 2024, with tirzepatide at 64.8% and semaglutide at 58.6%. The share of patients with at least 80% of days covered rose from 30.2% to 55.5%.
The authors credit resolved supply shortages, better dose escalation, improved side-effect management and lifestyle programs. Several of those levers sit with the care team rather than the drug. That matters because the orthopedic signal above only appeared with sustained use: one year of therapy moved the needle, three years moved it much further. Persistence is not a side issue in the outcomes story. It is the mechanism that makes the outcomes possible.
Employers Are Voting With Their Plan Designs
None of this has slowed the retreat on the payer side. The Business Group on Health's latest employer survey of 127 large employers covering 8.7 million people found that coverage of GLP-1s for obesity fell from 72% in 2025 to 60% in 2026, as reported by Word & Brown on September 8. Fourteen percent have dropped or plan to drop coverage for weight management by 2027, up from 10% earlier in the year, and another 24% have never offered it. Starbucks will discontinue weight-loss GLP-1 coverage beginning in October 2026.
"At the end of the day, the biggest issue is cost. We wouldn't be having this conversation about metformin."
Eileen Pincay, Pharmacy Practice Leader, Segal
The arithmetic behind that sentiment is blunt. Injectable GLP-1s typically cost $1,000 to $1,500 a month, employers usually cover 70% to 100% of that, pharmacy already represents 25% of total employer healthcare spending, and employer drug costs were estimated to rise 12% in 2026. A knee replacement avoided in year eight does little for a benefits budget that resets every January, particularly when the average employee may change jobs well before then. The result is a timing mismatch: the evidence accrues over years, while the coverage decision is made over quarters.
What Life Sciences Leaders Should Do Now
- Build the long-horizon evidence deliberately: Duration-dependent outcomes such as avoided arthroplasty will not surface in typical pivotal trials. Plan real-world studies with multi-year follow-up and pre-register the endpoints payers actually price.
- Make persistence part of the value proposition: The doubling in one-year persistence tracked better titration and side-effect support. Titration protocols and adherence programs belong in the commercial offer, not just the patient support budget.
- Segment the outcomes story by payer horizon: Self-insured employers weigh near-term costs, while Medicare and long-tenure plans capture later savings. Lead each audience with the outcomes that land inside its budget window.
- Be candid about molecule trade-offs: The head-to-head data show a real efficacy and safety trade-off. Sponsors that equip prescribers to individualize choice will earn more payer trust than those that argue one agent fits all.
- Partner on outcomes-based arrangements: Where employers balk at open-ended spend, warranties or rebates tied to persistence, weight maintenance or musculoskeletal outcomes can convert the evidence into terms a benefits committee can approve.
The GLP-1 class has reached an unusual point: the clinical rationale for sustained treatment keeps improving while access through commercial plans keeps narrowing. The companies that close that gap will be the ones that treat real-world evidence, adherence and payer economics as a single strategy rather than three separate workstreams.
